These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 7834962)
21. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. de Leon J; Spina E; Diaz FJ J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070 [No Abstract] [Full Text] [Related]
22. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Schwartz JB Clin Pharmacol Ther; 2007 Jul; 82(1):87-96. PubMed ID: 17495875 [TBL] [Abstract][Full Text] [Related]
23. Chirality--a new era of therapeutics. Agrawal YK; Bhatt HG; Raval HG; Oza PM; Gogoi PJ Mini Rev Med Chem; 2007 May; 7(5):451-60. PubMed ID: 17504180 [TBL] [Abstract][Full Text] [Related]
24. Chirality and its importance in drug development. Campbell DB; Wilson K Biochem Soc Trans; 1991 Apr; 19(2):472-5. PubMed ID: 1889635 [No Abstract] [Full Text] [Related]
26. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view. Shah RR Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705 [TBL] [Abstract][Full Text] [Related]
27. Biocatalysis: synthesis of chiral intermediates for drugs. Patel RN Curr Opin Drug Discov Devel; 2006 Nov; 9(6):741-64. PubMed ID: 17117684 [TBL] [Abstract][Full Text] [Related]
28. The pharmacological and toxicological significance of the stereochemistry of drug disposition. Caldwell J; Winter SM; Hutt AJ Xenobiotica; 1988 Jan; 18 Suppl 1():59-70. PubMed ID: 3344590 [No Abstract] [Full Text] [Related]
29. Pharmaceutical applications of AC biosusceptometry. Corá LA; Américo MF; Romeiro FG; Oliveira RB; Miranda JR Eur J Pharm Biopharm; 2010 Jan; 74(1):67-77. PubMed ID: 19482083 [TBL] [Abstract][Full Text] [Related]
30. PBPK models for the prediction of in vivo performance of oral dosage forms. Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672 [TBL] [Abstract][Full Text] [Related]
31. Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods. Coelho MM; Fernandes C; Remião F; Tiritan ME Molecules; 2021 May; 26(11):. PubMed ID: 34070985 [TBL] [Abstract][Full Text] [Related]
32. Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label. Menon-Andersen D; Yu B; Madabushi R; Bhattaram V; Hao W; Uppoor RS; Mehta M; Lesko L; Temple R; Stockbridge N; Laughren T; Gobburu JV Clin Pharmacol Ther; 2011 Sep; 90(3):471-4. PubMed ID: 21796114 [No Abstract] [Full Text] [Related]
33. Role of nanotechnology in pharmaceutical product development. Devalapally H; Chakilam A; Amiji MM J Pharm Sci; 2007 Oct; 96(10):2547-65. PubMed ID: 17688284 [TBL] [Abstract][Full Text] [Related]
34. Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions. Baneyx G; Fukushima Y; Parrott N Future Med Chem; 2012 Apr; 4(5):681-93. PubMed ID: 22458685 [TBL] [Abstract][Full Text] [Related]
35. The importance of biopharmaceutics in pharmaceutical education. Mezei M Pharmazie; 1971 Nov; 26(11):656-8. PubMed ID: 5154315 [No Abstract] [Full Text] [Related]